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A regional quality improvement effort to increase
beta blocker administration before vascular surgery
Philip P. Goodney, MD, MS,a,b Jens Eldrup-Jorgensen, MD,c Brian W. Nolan, MD, MS,a,b
Daniel J. Bertges, MD,d Donald S. Likosky, PhD,a,b and Jack L. Cronenwett, MD,a,b for the Vascular
Study Group of New England, Lebanon and Hanover, NH; Portland, Me; and Burlington, Vt
Objective: To determine if a regional quality improvement effort can increase beta-blocker utilization prior to vascular
surgery and decrease the incidence of postoperative myocardial infarction (POMI).
Methods: A quality improvement effort to increase perioperative beta blocker utilization was implemented in 2003 at centers
participating in the Vascular Study Group of New England (VSGNE). A 90% target was set and feedback given at biannual
meetings. Beta blocker utilization (<1monthpreoperative versus chronic) andPOMI rateswere prospectively collected for patients
undergoing open abdominal aortic aneurysm (AAA) repair (n 926) and lower extremity bypass (LEB; n 2,123) from 2003
through2008.PredictorsofPOMIweredeterminedusingmultivariate logistic regression.Ratesofbetablocker administrationand
POMI were analyzed over time, and across strata of patient risk based on a multivariate model.
Results: Perioperative beta blocker treatment increased from 68% of patients in the first 3 months of 2005 to 88% by the
last 3 months of 2008 (P < .001). In 2003, 44% of patients not on chronic beta blockers were treated with preoperative
beta blockers; by 2008, 78% of patients not on chronic beta blockers were started perioperatively on these medications
(P < .001). Beta blocker utilization increased across all centers and surgeons participating during the study period, and
increased in patients of low, medium, and high cardiac risk. However, the rate of POMI did not change over time (5.2%
in 2003, 5.5% in 2008; P  .876), although a trend towards lower POMI rate was seen in patients on preoperative beta
blockers (4.4% in 2003-2005, 2.6% in 2006-2008; P  .43). In multivariable modeling we found that age >70 (odds
ratio [OR], 2.1), positive stress test (OR, 2.2), congestive heart failure (CHF; OR, 1.7), chronic beta blocker
administration (OR, 1.7), resting heart rate<70 (OR, 1.8), and diabetes (OR, 1.6) were associated with POMI. Resting
heart rate was similar for patients on chronic (67), preoperative (70), and no beta blockers (70; P  .521).
Conclusions: Our regional quality improvement effort successfully increased perioperative beta blocker utilization.
However, this was not associated with reduced rates of POMI or resting heart rate. While this demonstrates the
effectiveness of regional quality improvement efforts in changing practice patterns, further work is necessary to more
precisely identify those patients who will benefit from beta blockade at the time of vascular surgery. (J Vasc Surg 2011;
53:1316-28.)
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aThe use of perioperative beta blocker therapy in patients
undergoing vascular surgery has been a topic of intense inter-
est among patients, surgeons, payers, and policy makers.1-4
Several randomized trials and large observational studies of
beta blocker use have demonstrated significant reductions in
postoperative cardiovascular morbidity and mortality, espe-
cially in patients with high risk of adverse cardiac events.5-14
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1316hese benefits, with seemingly few adverse events in earlier
tudies,8,12 were sufficient to procure endorsement for the
road use of perioperative beta blockade from several national
uality improvement initiatives, including the Leapfrog
roup,15 the American Medical Association,16 and the Sur-
ical Care Improvement Project,17 a collaborative of several
rganizations, including the Centers for Medicare and Med-
caid Services (CMS), the AmericanHospital Association, and
he Institute for Healthcare Improvement. Further, perioper-
tive beta blocker therapy was reported as a class I or II
ecommendation of the American College of Cardiology
oundation/America Heart Association1 in 2007, and simi-
arly endorsed by the European Society of Cardiology and the
uropean Society of Anesthesiology in 2010.18
Based on these recommendations, the Vascular Study
roup of New England (VSGNE) began a quality improve-
ent project in 2003 aimed at broadly implementing the
vidence-based utilization of beta blockers in patients under-
oing vascular surgery. We used evidence-based reviews of
erioperative beta blockade studies, surgeon and hospital
enchmarking, and discussions at our biannual meetings to
ncourage participating surgeons to achieve a target of 90%
eta blocker administration in patients undergoing abdominal
ortic aneurysm repair and lower extremity bypass (LEB). By
ncreasing the administration of beta blockers, we hoped to
c
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vascular surgery in our region.
METHODS
Subjects and databases. We utilized data collected pro-
spectively by the VSGNE, a regional cooperative quality im-
Table I. Patient characteristics, by procedure type and bet
Variable
O
Total (%)
Percent
beta
Male gender 676 (73.00) 384
Non-White race 7 (0.76) 4
Not living home preoperatively 1 (0.11) 0
Not independantly ambulatory
preoperatively NA
Age
Age 40 1 (0.11) 1
Age 40-50 6 (0.65) 4
Age 50-60 75 (8.10) 42
Age 60-70 300 (32.40) 179
Age 70-80 431 (46.54) 245
Age 80-90 112 (12.10) 63
Age 90-100 1 (0.11) 1
Smoking (prior or current) 849 (91.68) 494
Chronic obstructive pulmonary disease 345 (37.26) 191
Diabetes
Nondiabetic 786 (84.88) 449
Non-insulin dependant diabetics 128 (13.82) 79
Insulin-dependant diabetics 12 (1.30) 7
Coronary disease 326 (35.21) 233
Congestive heart failure 66 (7.13) 50
Preoperative medication regimen
Anti-platelet agent use 666 (71.92) 410
Preoperative statin use 542 (58.53) 358
Preoperative cardiac stress test
None performed 260 (28.08) 141
Performed, normal 489 (52.81) 279
Performed, abnormal 168 (18.14) 109
Operative characteristics:open
abominal aortic aneurysm repair
Aneurysm size 5.5 cm 250 (27.00) 137
Aneurysm size 5.5-6.5 cm 405 (43.74) 247
Aneurysm size 6.5 cm 256 (27.65) 142
Need for infrarenal clamp 693 (74.8%) 394
Need for suprarenal clamp 232 (25.2%) 140
Operative characteristics: lower
extremity bypass
Claudication NA
Tissue loss/rest pain NA
Above-knee popliteal recipient NA
Below-knee popliteal or lower
recipient NA
Conduit NA
Autogenous vein NA
Prosthetic NA
Preoperative cardiac risk stratification
(predicted risk of POMI)
Low predicted POMI risk 231 (24.9%) 122
Medium predicted POMI risk 464 (50.1%) 266
High predicted POMI risk 231 (24.9%) 147
aP value from chi-square test.provement initiative developed by community and academic wenters in 2002 to study regional outcomes in vascular surgery.
urther details on this registry have been published previously,19
nd others are available at http://www.vsgne.org.
The goal of this quality improvement effort was to
mprove the administration of beta blockers periopera-
ively. At the outset of our quality improvement initiative,
cker administration
n (%)
bdominal aortic aneurysm repair (N  926)
ronic
er
Percent on perioperative
beta blocker
Percent not on
beta blocker P valuea
0) 224 (33.14) 68 (10.06) .474
4) 1 (14.29) 2 (28.57) .224
0 (0) 1 (100) .013
NA NA NA
) 0 (0) 0 (0) .994
7) 2 (33.33) 0 (0)
0) 26 (34.67) 7 (9.33)
7) 91 (30.33) 30 (10.00)
4) 140 (32.48) 46 (10.67)
5) 37 (33.04) 12 (10.71)
) 0 (0) 0 (0)
9) 272 (32.04) 83 (9.78) .217
6) 121 (35.07) 33 (9.57) .290
2) 260 (33.08) 77 (9.80) .449
2) 33 (25.78) 16 (12.50)
3) 3 (25.00) 2 (16.67)
7) 71 (21.78) 22 (6.75) .001
6) 12 (18.18) 4 (6.06) .009
6) 204 (30.63) 52 (7.81) .001
5) 151 (27.86) 33 (6.09) .001
3) 83 (31.92) 36 (13.85) .001
6) 164 (33.54) 13 (9.41)
8) 46 (27.38) 13 (7.74)
0) 83 (33.20) 30 (12.00) .421
9) 123 (30.37) 35 (8.64)
7) 87 (33.98) 27 (10.55)
%) 225 (32.5%) 74 (10.4%) .032
) 71 (30.6) 21 (9.1%)
NA NA
NA NA
NA NA
NA NA
NA NA
NA NA
NA NA
1) 87 (37.9%) 22 (9.5%) .004
%) 157 (33.8%) 41 (8.8%)
%) 52 (22.5%) 32 (13.9)a blo
pen a
on ch
block
(56.8
(57.1
(0)
NA
(100
(66.6
(56.0
(59.6
(56.8
(56.2
(100
(58.1
(55.3
(57.1
(61.7
(58.3
(71.4
(75.7
(61.5
(66.0
(54.2
(57.0
(64.8
(54.8
(60.9
(55.4
(56.9
(60.3
NA
NA
NA
NA
NA
NA
NA
(52.8
(57.3
(63.6e sought to increase beta blocker usage in all patients
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dures in which the risk of cardiac complications is highest
 open abdominal aortic aneurysm repair (OAAA) and
LEB. In patients undergoing OAAA and LEB within the
VSGNE, we collected over 70 preoperative, intraopera-
Table I. Continued.
Variable Total (%)
Male gender 1479 (69.67)
Non-White race 18 (0.85)
Not living home preoperatively 77 (3.63)
Not independantly ambulatory
preoperatively
Age
Age 40 533 (25.11)
Age 40-50 13 (0.61)
Age 50-60 111 (5.23)
Age 60-70 394 (18.56)
Age 70-80 561 (26.42)
Age 90-100 669 (31.51)
Smoking (prior or current) 345 (16.25)
Chronic obstructive pulmonary disease 30 (1.41)
Diabetes
Nondiabetic 1747 (82.29)
Non-insulin dependant diabetics 645 (30.38)
Insulin-dependant diabetics 999 (47.06)
Coronary disease 552 (26.00)
Congestive heart failure 572 (26.94)
Preoperative medication regimen
Anti-platelet agent use 868 (40.89)
Preoperative statin use 393 (18.51)
Preoperative cardiac stress test
None performed 1529 (72.02)
Performed, normal 1235 (58.17)
Performed, abnormal 1321 (62.25)
Operative characteristics:open
abominal aortic aneurysm repair
Aneurysm size ,5.5 cm 494 (23.28)
Aneurysm size 5.5-6.5 cm 296 (13.95)
Aneurysm size .6.5 cm NA
Need for infrarenal clamp NA
Need for suprarenal clamp NA
Operative characteristics: lower
extremity bypass
Claudication NA
Tissue loss/rest pain NA
Above-knee popliteal recipient 449 (28.9%)
Below-knee popliteal or lower
recipient
1510 (71.1%)
Conduit 452 (21.3%)
Autogenous vein 1669 (78.6%)
Prosthetic 1532 (72.2%)
Preoperative cardiac risk stratification
(predicted risk of POMI)
590 (28.7%)
Low predicted POMI risk 579 (27.2%)
Medium predicted POMI risk 993 (46.8%)
High predicted POMI risk 550 (25.2%)tive, and postoperative variables and entered this data in dur regional dataset, as described in previous work.20
hese variables were used to describe patient character-
stics, and to allow us to perform cardiac risk stratifica-
ion,21 evaluate operative details and outcomes, and
ssess operative risk. These variables, stratified by proce-
n (%)
Lower extremity bypass (N  2,123)
ent on chronic beta
blocker
Percent on
perioperative
beta blocker
Percent
not on
beta
blocker P valuea
857 (57.98) 405 (27.40) 216 (14.61) .008
10 (55.56) 6 (33.33) 2 (11.11) .709
49 (63.64) 17 (22.08) 11 (14.29) .614
358 (67.17) 108 (20.26) 67 (12.57) .001
2 (15.38) 6 (46.15) 5 (38.46) .001
49 (44.14) 27 (24.32) 35 (31.53)
214 (54.31) 110 (27.92) 70 (17.77)
328 (58.57) 157 (28.04) 75 (13.39)
421 (62.93) 148 (22.12) 100 (14.95)
206 (59.71) 92 (26.67) 47 (13.62)
15 (50.00) 9 (30.00) 6 (20.00)
1016 (58.19) 456 (26.12) 274 (15.69) .801
385 (59.78) 160 (24.84) 99 (15.37) .621
503 (50.35) 289 (28.93) 207 (20.72) .001
351 (63.59) 137 (24.82) 64 (11.59)
381 (66.73) 123 (21.54) 67 (11.73)
618 (71.20) 175 (20.16) 75 (8.64) .001
282 (71.76) 70 (17.81) 41 (10.43) .001
923 (60.37) 406 (26.55) 200 (13.08) .001
794 (64.34) 291 (23.58) 149 (12.07) .001
746 (56.52) 338 (25.61) 236 (17.88) .001
273 (55.26) 144 (29.15) 77 (15.59)
210 (70.95) 64 (21.62) 22 (7.43)
NA NA NA NA
NA NA NA
NA NA NA
NA NA NA
NA NA NA
223 (49.7%) 139 (30.9%) 87 (19.3%) .524
925 (61.2%) 371 (24.5%) 214 (14.2%)
245 (56.3%) 108 (24.8%) 82 (18.8%) .625
979 (58.9%) 435 (26.1%) 254 (15.2%)
895 (58.4%) 399 (26.1%) 238 (15.5%) .635
340 (57.6%) 150 (25.4%) 100 (16.9%)
292 (50.4%) 173 (29.9%) 114 (19.7%) .000
590 (59.4%) 265 (26.7%) 138 (13.9%)
353 (64.2%) 111 (25.9%) 86 (15.6%)Percure type and use of beta blockade, are shown in Table I.
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We formally began our quality improvement effort in beta
blocker utilization in 2003, at the six centers participating
in the VSGNE at its inception. After we analyzed and
discussed the evidence for beta blocker usage in 2003, we
selected 90% as our target for perioperative beta blocker
administration, to allow for drug intolerance in some pa-
tients. Use of beta blockers was recorded in the VSGNE
dataset preoperatively, at discharge, and at 1-year follow
up.Dosage was not recorded. Resting heart rate at arrival to
the operating room, as well as peak heart rate intraopera-
tively, was recorded beginning in July 2005. Beta blocker
treatment initiated within 1 month of surgery was catego-
rized as a “preoperative”; beta blockers started more than 1
month prior to surgery were categorized as “chronic.”
While our quality improvement initiative recommended
that metoprolol 25 mg twice daily be started 2 weeks prior
to operation and be continued following operation, sur-
geons were left to their own discretion in regards to agent,
dose, timing, and titration to heart rate.
A central tenet of our quality improvement interven-
tion was to provide feedback to surgeons and centers.
Therefore, rates of utilization (either chronic or preopera-
tive) were reported back to individual surgeons and centers
on a biannual basis. While individual surgeon and center
results were kept anonymous, regional, institutional, and
individual rates (blinded) of beta blockade were reviewed in
detail at biannual meetings, when methods for increasing
utilization were discussed and successful methods were
shared, such as preprinted order sheets or prescription
forms. All six centers that began the quality improvement
initiative remained in the study during the entirety of the
study period.
Main outcome measures. Our study examined two
main outcome measures. The first was the utilization of
perioperative beta blockers, measured as the proportion of
patients on beta blockers, either chronic or preoperatively.
This outcome was examined across strata of surgeons,
centers, type of beta blockade use (preoperative or
chronic), and procedure (AAA and LEB). We included
only surgeons (n  29) and centers (n  6) who were
present in the cohort during the entire period of the analysis
in order to not confound the impact of quality improve-
ment in the same group over time.
Second, given that the ultimate goal of our quality
improvement intervention was to decrease patient morbid-
ity and mortality, we measured in-hospital, postoperative
myocardial infarction (POMI) rates (defined by electrocar-
diographic, echocardiographic, or troponin-based evidence
of myocardial infarction in the postoperative period). Sim-
ilar strata were compared as in the beta blockade analysis
(surgeon, center, type of beta blocker therapy, and proce-
dure).
Analysis. Overall, 946 patients underwent OAAA and
2,215 underwent LEB between January 1, 2003 and De-
cember 31, 2008 within the initial six centers of VSGNE.
Within this group, 926 OAAA patients (95% of the total)
and 2,123 LEB patients (96% of the total) had information pvailable about beta blocker administration, POMI, and
atient characteristics available for analysis during the entire
ime period, and therefore constituted our cohort for anal-
sis.
We compared beta blocker administration over time,
sing non-parametric tests of trend. To further examine
hanges over time, we used statistical process control (SPC)
ethods. SPC is a methodology used commonly in manu-
acturing to examine process variation.22 Using control (p)
harts, we examined the proportion of patients taking beta
lockers over time, in 3-month intervals. We assumed the
rocess was stable at initiation of the process, given that
ractice patterns had not changed significantly across sur-
eons prior to the initiation of our study, based on the
eport of our quality improvement initiative working
roup. Upper and lower control limits were defined as
-sigma (standard deviations) above and below the control
alue, respectively, and used theWestern Electric Company
ules to determine if the outcomes had moved beyond their
ontrol limits.22-24 These rules state that if two of three
onsecutive points fall outside a 2-sigma limit, or if 4 of 5
onsecutive points fall beyond 1-sigma limits, or if eight
oints fall on one side of the centerline, then a significant
hange has occurred in the process beingmeasured. On our
ontrol charts, those points that are significantly different
han the baseline are shown as red diamonds.
We used a similar methodology to examine the incidence
f cardiac complications over time in patients on chronic or
reoperative beta blockade, as well as patients not on beta
lockers. In order to categorize patients according to their
ardiac risk we developed a logistic regression model to pre-
ict the risk of POMI, based on the characteristics of patients
ho experienced POMI. This model was used to categorize
atients into low (2.5%-5.0% predicted risk of POMI), me-
ium (5.0%-11.5%predicted risk of POMI), andhigh (11.5%-
5.1% predicted risk of POMI) risk categories, to allow eval-
ation of changes in beta blockade across different risk strata
f cardiac risk. Our POMI model demonstrated good dis-
rimination (area under Receiver Operating Characteristic
urve  0.71), and the calibration of the model was satisfac-
ory across a broad spectrum of patient risk (R2  0.99,
osmer-Lemeshow goodness of fit test P .40; see Supple-
ental Fig 1, online only).
All analyses were performed using Microsoft Excel
Redmond, WA) and Stata (College Station, Tex). The
nstitutional Review Board at Dartmouth Medical School
eviewed and approved our study protocol.
ESULTS
Patient characteristics. In the OAAA cohort, patients
ere most commonly male (73%), mean age was 71 years,
nd nearly all were Caucasian (Table I). Most patients had
history of either prior or current smoking (92%). About
alf of patients had a history of diabetes, 40% had coronary
isease, and nearly a third had a history of chronic obstruc-
ive pulmonary disease. Most patients were on antiplatelet
gents (72%) and statin therapy (58%). Based on their
redicted risk of POMI, 50% of patients had intermediate
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cohort used are available in Table I.
Similarly, in the LEB cohort, patients were most com-
monly male (69%), mean age was 69 years, and nearly all
were Caucasian. Nearly all patients had a history of either
prior or current smoking (83%). About half of patients had
a history of diabetes, 41% had coronary disease, and nearly
a third had a history of chronic obstructive pulmonary
disease. Most patients were on antiplatelet agents (72%)
and statin therapy (58%). While the overall predicted risk of
cardiac complications was slightly higher in these patients
as compared with those undergoing OAAA, based on their
predicted risk of POMI, 46% of LEB patients had interme-
diate cardiac risk (Table I).
Beta blocker utilization. At the time of initiation of
our quality improvement initiative in 2003, the overall rate
of perioperative beta blocker utilization was 68%.However,
by the end of our study period, beta blocker use had
increased to 88% (P .001; Fig 1). Using SPC to evaluate
changes over time, we noted that by December of 2005, a
significant increase in the perioperative usage of beta block-
ers had occurred. This increase in beta blocker therapy
remained above the baseline from 2005 until the comple-
tion of our study period in 2008, indicating that the process
Fig 1. Control P, chart, demonstrating beta blocker adm
rate over time. Central tendency is shown in the blue line,
central tendency has occurred. The red lines indicate the
1-sigma and 2-sigma differences from baseline.of beta blocker administration in our region had changed pignificantly during the study period (Fig 1). This effect was
pparent across all centers and surgeons in our study (Fig 2,
and B).
When we examined the rates of beta-blocker utiliza-
ion by pattern of utilization (chronic versus preopera-
ive), we found an increase over time in both chronic
54% in 2003, 61% in 2008; P  .004) and preoperative
sage (20% in 2003, 31% in 2008; P  .001). We
elieved that our intervention was most likely to affect
he use of preoperative beta blockers, as compared with
hose patients already on chronic beta blockers. We
ound that in 2003, 44% of patients not on chronic beta
lockers were treated with perioperative beta blockers.
owever, by 2008, 78% of patients not on chronic beta
lockers were started preoperatively on these medica-
ions (Fig 3). This effect was consistent across all centers.
Next, we analyzed changes in beta blocker administra-
ion across low, medium, and high cardiac risk patients
Table II). Although the use of beta blockers increased in
ll categories, statistically significant increases in the use of
reoperative beta blockers were most apparent in low-risk
atients, while statistically significant increases in chronic
eta blocker use were seen in medium- and high-risk pa-
ients (Table II). Lastly, we examined the proportion of
ration and postoperative myocardial infarction (POMI)
the red diamonds demonstrating significant change from
r and lower control limits, while the gray lines indicateinist
with
uppeatients discharged from the hospital on beta blocker ther-
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Volume 53, Number 5 Goodney et al 1321apy. Overall, we found that patients who were on beta
blockers prior to surgery were very likely (89% of all pa-
tients) to be discharged on these medications. Of those
patients who were not on beta blockers at the time of
surgery, 33% were subsequently discharged on beta blocker
therapy.
Effect of beta blockade on postoperative myocar-
dial infarction. Overall, POMI occurred relatively infre-
quently in our cohort (5.5%). Patients undergoing
OAAA were slightly more likely to experience POMI
than patients undergoing LEB (7.6% vs 4.6%; P .001).
Despite the increase in usage of beta blockers, we found
that no significant change occurred in the rate of POMI
over time (Fig 1). While there was a trend for a reduced
POMI rate in patients on preoperative beta blockers, in
patients of low, medium, and high cardiac risk, these
changes were not statistically significant (Table III).
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Fig 2. A, Center-specific beta blockade administratio
administration, in 2003 and 2008.However, among the small group of patients not on beta ulockers in the intermediate cardiac risk group, the rate
f POMI was significantly higher in 2006 to 2008 as
ompared with 2003 to 2005 (7.4 vs. 1.6%). Conversely,
atients on preoperative beta blockers experienced a
eduction in the rate of POMI during the same time
eriod (4.6% in 2003-2005, 2.5% in 2006-2008; P 
23; see Table III).
Effect of beta blockade on heart rate. Despite the
ncrease in utilization of beta blockade, we found no
ignificant differences in resting or peak intraoperative
eart rate over time during our study interval (Table IV).
n all patients in our study cohort, heart rate on arrival to
he operating room was relatively low in the early years, and
id not change significantly in later years (resting heart rate
9 in 2005, resting heart rate 68 in 2006-2008; P .412).
Overall rate of POMI, by pattern of beta blocker
se. Rates of POMI varied by the type of beta blocker
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POMI was highest in patients on chronic beta blockers.
Patients on chronic beta blockers were nearly twice as
likely to experience POMI when compared with patients
44%
59%
69
0
0.25
0.5
0.75
2003 2004 200
PRE-OPERAT
Pr
op
or
tio
n 
(%
)
-------------------------------------------------------------
Fig 3. Rate of preoperative beta blocker use
Table II. Beta blocker utilization, stratified by risk of post
Predicted
Low (2.5%-3.2%)
2003-2005 2006-2008 P value
No beta blocker 23% 11% .01
Preoperative beta blockers 28% 36% .01
Chronic beta blockers 49% 53% .18
Table III. Postoperative myocardial infarction, by beta bl
Predicted
Low (predicted risk of 2.5%-3.2%)
2003-2005 2006-2008 P value
No beta blocker 2.3% 0.0% .14
Preoperative beta blockers 1.8% 0.7% .42
Chronic beta blockers 2.5% 2.3% .89
Table IV. Heart rate, by beta blocker use and year
Arrival heart rate (mean
2003-2005 2006-2008
No beta blocker 72 (68-76) 69 (66-71)
Preoperative beta blockers 72 (69-75) 69 (68-72)
Chronic beta blockers 67 (65-69) 67 (65-69)
CI, Confidence interval.on no beta blocker (6.9% vs 3.9%; P  .001) or preop- prative beta blocker (6.9% vs 3.4%; P  .001) This trend
ersisted, even when we studied this effect across differ-
nt categories of cardiac risk, as shown in Fig 4, B. The
ost dramatic differences in POMI rates were seen in the
80%
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.001 -------------------------------------------------------------
tients not already on chronic beta blockers.
ative myocardial infarction
of postoperative myocardial infarction
Medium (5.0%-11.5%) High (13.1%-15.1%)
2005 2006-2008 P value 2003-2005 2006-2008 P value
% 8% .01 21% 6% .01
% 30% .45 19% 24% .09
% 62% .01 60% 70% .01
use and cardiac risk
of postoperative myocardial infarction
rmediate (predicted risk of
5.0%-11.5% )
High (predicted risk of
13.1%-15.1%)
2005 2006-2008 P value 2003-2005 2006-2008 P value
% 7.4% .05 8.6% 8.3% .95
% 2.5% .23 7.3% 6.2% .77
% 4.7% .56 12.2% 15.1% .34
CI) Maximum heart rate (mean, 95% CI)
P value 2003-2005 2006-2008 P value
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ents and the remaining patients.
Factors associated with POMI. Using multiple lo-
gistic regression, we identified several preoperative patient
characteristics associated with POMI in multivariate analy-
sis. As shown in Table V, age over 70, a positive preopera-
tive stress test, congestive heart failure, and a resting heart
rate less than 70 were all associated with increasing risk of
POMI. Moreover, we also found that the chronic admin-
istration of beta blockers was also associated with higher
risks of POMI. This effect persisted, even when we adjusted
for heart rate, by including this variable in our regression
3.9%
0
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Fig 4. A, Postoperative myocardial infarction (POMI) r
blocker use and cardiac risk strata.
Table V. Multivariate predictors of postoperative
myocardial infarction
Odds
ratio
95% conference
interval P value
Diabetes 1.6 1.1-2.6 .026
Congestive heart failure 1.7 1.1-2.5 .008
Chronic beta blocker use 1.7 1.2-2.4 .006
Resting heart rate  70 1.8 1.1-2.8 .005
Age 70 2.1 1.5-2.9 .001
Positive stress test 2.2 1.5-3.2 .002model. mISCUSSION
We found that a quality improvement effort was
roadly effective in increasing the use of perioperative beta
lockers in patients undergoing LEB and OAAA in our
egion. This effect was seen for each of the hospitals and
urgeons participating in the initiative, and was seen across
ll strata of patient cardiac risk. However, the absolute
ncrease in utilization of perioperative beta blockers was
ost significant in patients with the lowest cardiac risk, and
verall our quality improvement effort did not result in a
ecline in the rate of POMI.
Given the uniform increase in utilization of beta block-
rs in our region, we believe that were very successful in
eveloping and executing a quality improvement initiative
o change the way care is delivered to our patients. Several
recedents for this methodology exist,25-27 and these ef-
orts served to guide our initiative. In 1996, O’Connor et al
escribed a regional quality improvement initiative wherein
eedback of outcome data, training in continuous quality
mprovement techniques, and site visits was associated with
24% reduction in hospital mortality after coronary bypass
urgery. Several other similar initiatives have demonstrated
imilar effects across a broad spectrum of surgical and
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quality improvement. The techniques for process change in
VSGNE included informational sessions at our biannual
meetings, quality improvement discussions, and, most im-
portantly we believe, biannual individualized feedback with
anonymous benchmarking of the surgeon, institution, and
regional use of beta blockers. This low-cost intervention
resulted in significant improvements in the use of beta
blockers across all centers, regions, and patient cardiac risk
strata in our region.
However, we were disappointed to find that, despite
this successful effort, the rate of POMI did not decrease
over time. Why did our quality improvement effort not
achieve a decline in the rate of POMI? While the answer to
this question is unknown, we have several potential expla-
nations. First, our beta blocker dosage regimen may have
been too low. In the literature, there are a number of
different agents used, different dosages, and timing of
administration, and several trials have titrated beta blocker
dosage to heart rate.5 In an effort to maximize surgeon
compliance, we selected a standardized fixed regimen with
a relatively low dose, in an effort to minimize side effects.
While this served as a convenient and effective tactic to
maximize the ease of implementing beta blocker therapy, it
is possible that this dose was not large enough to have an
effect, and the lack of measurable difference in heart rate
during the study interval attests to this possibility.
Second, while our intervention sought to achieve an
increase in overall beta blocker utilization, most often this
change occurred in low- and intermediate-risk patients. In
a retrospective review of over 600,000 patients in an ad-
ministrative, quality-focused database, Lindenauer showed
that beta blockers were most beneficial in high-risk pa-
tients, probably beneficial in intermediate-risk patients, and
of questionable value in low-risk patients.13 Poldermans
also showed a decrease in cardiac events with beta blocker
administration to high-risk patients undergoing vascular
surgery in a randomized clinical trial.4,8 In our region,
preoperative beta blocker use initiated within 30 days of
surgery in high-risk patients went from 19% to 24% (P 
.09). This change represented an increase of 33 “new”
high-risk patients on preoperative beta blockers, which was
likely too few to demonstrate a significant reduction in
cardiac events. Further, within the intermediate cardiac risk
group, a significant possibility exists that type II error
limited our ability to detect a difference in POMI rate.
Third, our study may have found that beta blockers
have little effect on POMI because that might be the “real”
answer. In the literature, there has been a transition in the
results from randomized clinical trials. Initially, the trials
showed a reduction of myocardial ischemia and myocardial
infarction.4,8,13 However, as time went on, two trials failed
to show a benefit.10,11 In these two randomized trials,
patients underwent aortic aneurysm repair and peripheral
vascular reconstruction, and therefore, the cohorts were
procedurally quite similar to our study. In the first study,
the perioperative beta blocker (POBBLE) trial investiga-
tors found no significant difference in adverse cardiovascu- tar events.10 In the second study, the Metoprolol after
ascular Surgery (MaVS) trial,11 there were no significant
eduction in cardiovascular events in a population under-
oing abdominal aortic repair and peripheral vascular re-
onstruction, again quite similar to our cohort. One of the
otential explanations for the lack of impact was the ab-
ence of high risk patients undergoing high risk operations.
ore recently, the PeriOperative ISchemic Evaluation
POISE) trial, the largest randomized clinical trial on peri-
perative beta blocker treatment published to date, found a
ignificant decrease in cardiac events from beta blocker
dministration (4.2% vs 5.7%; P  .001), but also showed
he beta blocker therapy was associated with an increase in
troke (1% vs 0.5%; P .005) and all cause mortality (3.1%
s 2.3%; P  .03).5 This trial was notable for a very large
ose of beta blocker (metoprolol 100 mg), given 2 to 4
ours preoperatively and the high rate of intraoperative
radycardia and hypotension, which likely contributed to
he increased incidence of postoperative stroke and all-
ause mortality. Our dataset was not initially configured to
apture the possible non-lethal complications of beta
locker therapy, such as stroke. While stroke was routinely
ollected as an outcome variable in carotid surgery, it was
ot studied in other procedures such as LEB. Accordingly,
e have since corrected this deficiency in our dataset.
urther, our dataset was also not configured to ensure
bsolute adherence to dosing regimens and heart rate titra-
ion.
What is the role of beta blockers in modern vascular
urgery? The American College of Cardiology/American
eart Association guidelines are to continue beta blockers
n patients who are on them (class I) and initiate beta
locker therapy titrated to heart rate in patients with coro-
ary artery disease or high cardiac risk (more than one
linical risk factor; class IIa).1 The usefulness of beta block-
rs is uncertain for patients in intermediate risk (one clinical
isk factor; class IIb) or at low risk (no clinical risk factors;
lass IIB). These recommendations are supported by the
uropean Society of Cardiology/European Society of An-
sthesiology with two slight differences. The initiation of
erioperative beta blocker therapy in patients with coronary
rtery disease or undergoing high risk surgery is considered
o be a class I recommendation, and treatment for interme-
iate risk surgery is a class IIa recommendation.18
Should we continue to administer beta blockers to all
atients undergoing vascular surgery? First, we must bal-
nce the potential risks and harms of administering beta
lockers to our patients. While our initiative was successful
n increasing the use of beta blockers, the increases in
erioperative beta blockade most commonly occurred
ithin the patients with the lowest cardiac risk. Accord-
ngly, we aim to use our quality improvement initiative to
ocus our efforts more accurately, choosing only interme-
iate- and high-risk patients for perioperative beta block-
de. Second, wemust look carefully at the risks presented to
atient by chronic administration of beta blockers. Our
nalyses showed that independent of complications related
o bradycardia or pre-existing ischemia, an association ex-
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POMI. Unmeasured confounders, such as hypotension
secondary to excessive beta blockade, may have played a
role in these excess events. Therefore, we have focused our
ongoing efforts towards understanding the events sur-
rounding POMI, using both our clinical dataset and chart-
based review, in the hopes of “drilling down” more pre-
cisely on the factors that allow us to predict and prevent
POMI. Third, our study demonstrates the feasibility and
efficacy of surgeon-led quality improvement, especially
when it is implemented in the context of a regional registry.
Therefore, our future work will continue to expand the use
of this method to implement other evidence-based prac-
tices, such as patching following conventional carotid end-
arterectomy,33,34 statin administration,35-37 and cell saver
use in OAAA.38
Finally, our study demonstrated that patients on
chronic beta blockers are more likely to have a POMI than
patients on perioperative beta blockers, or no beta blocker
at all. This association persisted, even when adjusting in our
multivariable models for other markers of cardiac disease
(such as congestive heart failure or a history of a positive
stress test), as well as clinical parameters such as adequate
heart rate control. It is possible in our dataset that the use of
chronic beta blocker is simply a more accurate proxy for
elevated cardiac risk, as measures such as preoperative con-
gestive heart failure or pre-existing coronary artery disease
may vary in nature or extent. However, it is also possible
that chronic beta blocker use itself is causative for cardiac
complications. Although we cannot be certain which expla-
nation is the right answer, we found little evidence to
suggest that chronic beta blockers were harmful – there was
no change in mortality over time in patients receiving
chronic beta blockers, and no evidence of higher stroke
rates or need for vasoactive medications perioperatively in
these groups. Our future efforts will seek to more precisely
quantify these relationships and attempt to understand
more completely the effect of chronic beta blockade utili-
zation on POMI.
Our study has limitations. First, as mentioned previ-
ously, we did not control for the type of beta blocker
administered, nor did we record dosage information, or the
precise duration of therapy, especially among patients re-
ceiving beta blockers preoperatively. While these specific
details would have been helpful, practical limitations as to
the reasonable length of our quality improvement dataset
precluded capturing these variables. However, evidence
from several systematic reviews39-41 and meta-analyses42-44
suggest that there are few dramatic differences in effect by
beta blocker type, and we did collect heart rate as a proxy
for effective dose of beta blockade. Second, variation in the
measurement of myocardial infarction, especially by serum
assays, may have differed across centers. However, while
the thresholds and laboratory values may have differed
across centers, we found little variation in the absolute
number of measurements of serum assays performed across
centers. Further, we used our biannual meetings as well as
annual data audits to ensure that POMIwas being collectedn a consistent manner, making systematic confounding by
urgeon, center, or risk strata unlikely. And third, our
opulation, composed of patients primarily from Northern
ew England, is not ethnically diverse. Therefore, espe-
ially given the differences in cardiovascular risk across
acial groups, the overall generalizability of our experience
o more racially diverse cohorts remains uncertain.
In conclusion, despite successfully implementing a re-
ional quality improvement initiative aimed at increasing
he utilization of perioperative beta blockers, we did not
ecrease the incidence of POMI. Our future work will
enter on expanding the use of regional registries as quality
mprovement tools in surgery, as well as further delineating
hich patients are best served by the administration of
erioperative beta blockade.
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Dr Gregory Moneta (Portland, Ore). One argument
against use of the perioperative beta blockers has been what
appears to be an increased risk of stroke in patients treated with
beta blockers. Perhaps beta blockers are preventing some small
MIs and other relatively minor cardiac events that don’t really
affect the patient’s quality of life at the risk of causing a stroke
that does affect their quality of life? Did you analyze for strokes
and quality of life in your study? Is it possible perioperative beta
blockers both solve and create problems and the overall effect is
a wash?
Dr Philip Goodney. We shared the same concern about
halfway through this project, when we realized that we were
collecting stroke data for some of the operations in our data set,
but not for all of them. Therefore, that outcome was added about
halfway through for all procedures.
The information that we have shows no effect, but we can’t say
that’s true over the entire length of the study.
In terms of your question about quality of life, it would be
optimal if we had SF-36 scores or some objective measure for
quality of life for all these patients; however, that is beyond the
scope of our project right now.
DrPeter Lawrence (Los Angeles, Calif). Your group hasmade
great contributions in the area of modifying risk factors. My
question has to do with the halo effect of using beta blockers. Do
you have evidence of what’s happened as far as use of statins and
antiplatelet agents? Could their use be a confounding factor in the
unexpected results that you got? Are they using more of these
other agents as well as the beta blockers?
Dr Goodney. We have seen increases, as some of my col-
leagues have presented before, in the use of antiplatelet agents and
statins. In our multivariable model, we saw no effect on postoper-
ative MI from those agents. However, we’re limited, fortunately in
some sense, in the number of high-risk patients that aren’t already
on those medications. Our ability to detect a difference from
statins and antiplatelet agents in terms of outcomes, like postoper-
ativeMI or death, is therefore compromised. It’s not a randomized
trial, and we didn’t have a control arm. So while we hope those
agents are helping, they didn’t have a definitive impact on post-MI
rate in this study.
Dr Sherif Sultan (Galway, Ireland). Regarding the group
who are prolonged on cardioselective beta blockade, they have
fared out so badly. From the results of the ARIC study and the
LIFE trial, it has been shown that cardioselective beta blockers
induce full-blown diabetes mellitus in up to 28% of normal
people. In the context of the results from these large-scale
prospective trials, you have shown in one of your Cox propor-
tional hazards models that diabetic patients have worse results.
Do you think cardioselective beta blockade was influential in
this adverse outcome and that the use of beta-blockers could
have caused your major side effect?
Dr Goodney. We wondered that same question as well. And
we did cross tabulations in that subgroup and saw no direct
relationship. Both of those effects existed independently in terms
of diabetes and beta blockers. So as to whether or not the betaDr Douglas Wooster (Toronto, Ontario, Canada). I think
uideline implementation is an important issue. Oftentimes we see
hat the centers that have the lowest compliance have the largest
mprovement with a guideline implementation strategy. And basi-
ally this is because there is a knowledge gap or perhaps a systems
ssue in those centers.
In your study, you’ve shown actually those groups did not get
p to the accepted level or the anticipated level, whereas you did
ee the incremental slight increase in those places that were doing
ery well. Did you have an explanation for that? Is there something
hat you would modify in taking your program forward, as you
ere saying in your conclusions, to try to improve compliance
cross-the-board with those places that were at the lowest end of
he group?
Dr Goodney. We set the 90% mark, knowing that we had
omewhere between a 5% and an 8% intolerance rate amongst
atients unable to tolerate beta blockers, and therefore the 90%
ark was arbitrary. We gave feedback to each surgeon and to each
enter, and their decision to use beta blocks was independent of
ur initiative. We simply reported the data and encouraged their
se; we didn’t mandate it. We saw increases across all surgeons and
ll centers. While not everybody came up to 90% and maybe there
ere, for whatever reason, a higher proportion of intolerant pa-
ients in some surgeon’s practices.
Dr Olaf Schouten (Rotterdam, The Netherlands). I was
truck by the high incidence of myocardial infarction with chronic
eta blockers. Do you have any information about patients who
ere withdrawn from beta blockers in the perioperative period?
ecause we know if patients have chronic beta blockers and you
top the beta blockade, that these patients have a very high risk of
erioperative MIs.
In your multivariate analysis, patients who have a heart rate
elow 70 beats/minute have a 1.8 increased risk for perioperative
I. It’s difficult for me to understand, because if you dose the beta
lockers correctly, you should be below the 70 beats/minute
hreshold. Do you have an explanation for this?
Dr Goodney. In terms of withdrawing beta blockers, we
on’t have that information and certainly, I suspect, as you alluded
o, that too would represent an even higher risk group.
In terms of heart rate, the reason we analyzed each incremen-
al heart rate, average heart rate was about 77 to 78, at least on
resentation. And the reason that we analyzed the variable was to
ee if the heart rate was very well controlled, if that would push beta
lockers out of the multivariable model. As you know, this would
est if heart rate, really the outcome of interest, was a stronger
redictor of postoperative MI than chronic beta blocker use. And
t turned out it didn’t. And so we really were left with the question:
s this some variable we’re not measuring? Is it BNP? Is it some
ther unmeasurable clinical quantity or is it the beta blockers
hemselves? And we still don’t know.
Dr StephenMurray (Spokane, Wash). So the simple question
s, does the emperor have no clothes?
You’ve just proven that you can increase compliance amongst
noncompliant group, and do so up to close to the 90% level – and
ade absolutely no difference in the long term outcome of these
atients. Have you not just proven the ineffectiveness of beta
lockade?
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May 20111328 GagneDr Goodney. If this was a randomized trial, my worry would
be yes. But, of course, we don’t have the control arm in this. And
we wondered how we might study that. This is a real world study,
so it’s a study in which you need not only highly selected patients
and centers of excellence, you would need real world data. So, to
get appropriately large-scale, one would essentially be limited to
administrative or claims data.
After 2005, Medicare Part D would have that informa-
tion available and you could conceivably study those on beta
blockers and those not on beta blockers. The other alternative
would be to implement another regional quality improvement
group that didn’t study beta blockers to see what happened over
time.
Dr Murray. We’ll look forward to it.
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ize” care pre-empted the wisdom of facts gained through multiple
subsequent, well-designed studies and analyses. Medicine may
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1Dr Jens Eldrup-Jorgensen (Portland, Ore). Our study did
ave a number of limitations which may explain the lack of impact
f perioperative beta blocks on postoperative myocardial infarc-
ion. The dose was somewhat low, which may have decreased the
ffectiveness of the medication. We had a relatively low number of
igh-risk patients undergoing high-risk operations, and those are
he ones who would be expected to benefit most from being
tarted on beta blockers prior to operation.
To address Dr. Moneta’s question regarding the issue of
troke in patients on perioperative beta blockers, in the POISE
tudy, they used a very high dose of beta blocker which probably
ontributed to hypotension and postoperative stroke. Although
ypotension has been seen in previous studies, POISE is the only
tudy which identified this high incidence of stroke.INVITED COMMENTARYPaul J. Gagne, MD, Norwalk, Conn
In the past decade, business interests and government policy
makers undertook to “refine” the delivery of health care by pro-
posing guidelines that would codify aspects of patient care delivery.
The proposed impetus was to improve quality and decrease costs
for treating conditions like congestive heart failure, surgical infec-
tions, and vascular surgery-related myocardial infarction. The as-
sumption implicit to these guidelines was that physicians and the
health care systems they participate in were not interested in or able
to improve health care with data-driven strategies. The club of
reimbursement was used to drive these quality initiatives, implying
that physician concern for the welfare of their patients was not
adequate to achieve good results.
The excellent article by Goodney et al1 highlights two very
important points to remember and publicize as we go forward in
the debate on health care reform.
The first is that intelligent, well-trained physicians are better
able to care for their patients than are committees who believe they
have a “special ability” to understand “evidence-based medicine.”
Physicians learn early in their training to read the literature with a
critical eye and to determine how best to apply new science to their
patients. Mandated guidelines are only as good as the data they are
based on. They are not able to accommodate specific patient needs,
nor are they nimble enough to adapt to new data the way individ-
ual physicians do daily. The guidelines urging beta-blockers for
vascular patients are a great example of how rushing to “standard-eem to change glacially at times, but I believe this reflects a careful
nd ongoing critical analysis by physicians of “new science” rather
han ignorance or indifference to patient welfare. We practice
vidence-based medicine daily. Unfortunately, the evidence is
ften not as straightforward as the media and pundits would
urport.
The second important point in this report is that physicians,
onvinced that a new therapy or approach is in their patients’ best
nterest, will adopt it. The physicians in this research consortium
uickly and effectively instituted beta-blocker use, expecting to
mprove their patients’ care. This occurred without financial incen-
ives.
I commend the authors for their scientific contribution on the
ole of beta-blockers in vascular surgery. I also thank them for
ffirming what I believe about our profession. As a group, physi-
ians, with our speciality societies, will do what is best for our
atients. We do not need “Big Brother” herding us to achieve this.
e are our patients’ best advocates and wemust resist the efforts of
oliticians, lawyers, business interests, and insurance vendors to
onvince society otherwise.
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Supplemental Fig 1 (online only). Correlation of observed and expected values for prediction model for
postoperative myocardial infarction (POMI).
